您的位置: 首页 > 2018年3月 第49卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

AMA-M2、SP100和GP210在诊断原发性胆汁性肝硬化中的应用评估

Evaluation of AMA-M2, SP100 and GP210 in the diagnosis of primary biliary cirrhosis

来源期刊: 广州医药 | 38-41 发布时间:2021-12-01 收稿时间:2025/11/13 17:23:26 阅读量:15
作者:
关键词:
原发性胆汁性肝硬化AMA-M2SP100GP210
Primary biliary cirrhosisAMA-M2SP100GP210
DOI:
10.3969/j.issn.1000-8535.2018.02.010
收稿时间:
2017-12-21 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 评估AMA-M2、SP100和GP210三种自身抗体在诊断原发性胆汁性肝硬化(primary biliary cirrhosis,PBC)中的应用价值。方法 收集我院近3年就诊患者的AMA-M2、SP100、GP210、ALP和GGT检测数据,其中PBC患者50例,非PBC肝胆疾病或自身免疫病患者226例,正常对照290例。分析这些检测指标对PBC诊断的敏感度和特异度。结果 AMA-M2、SP100和GP210诊断原发性胆汁性肝硬化的敏感度分别为96.00%、36.00%、8.00%,特异度分别为98.26%、97.87%、99.03%。PBC组病人的ALP和GGT检测结果高于非PBC病人组。结论 AMA-M2、SP100和GP210对PBC的临床诊断特异度较高;AMA-M2的敏感度高,但SP100和GP210敏感度低。
Objective To evaluate the diagnostic accuracy of AMA-M2, SP100 and GP210 for the primary biliary cirrhosis (PBC).Methods A total of 50 patients with PBC and 226 patients with other liver diseases or autoimmune diseases were enrolled in this study and 290 healthy individuals were included as normal controls. The data of AMA-M2, SP100, GP210, ALP and GGT were collected and analyzed for sensitivity and specificity in the diagnosis of PBC.Results The sensitivity and specificity of AMA-M2, SP100 and GP210 in the diagnosis of PBC were 96.00%, 36.00%, 8.00% and 98.26%, 97.87%, 99.03%, respectively. Compared to PBC group, the concentrations of ALP and GGT in non-PBC patients and controls were low.Conclusion AMA-M2 is quite accurate with high specificity and sensitivity in the diagnosis of PBC. However, SP100 and GP210 have high sensitivity but low sensitivity.
1、 张奉春,徐东,刘炜,等. 抗GP210抗SP100抗体与原发性胆汁性肝硬化活动性的相关性[J]. 中华风湿病学杂志, 2009,13(12):808-811. 张奉春,徐东,刘炜,等. 抗GP210抗SP100抗体与原发性胆汁性肝硬化活动性的相关性[J]. 中华风湿病学杂志, 2009,13(12):808-811.
2、 SAARE M, H?MARIK U, VENTA R, et al. SP140L, an Evolutionarily recent member of the sp100 family, is an autoantigen in primary biliary cirrhosis[J]. J Immunol Res, 2015,2015(12): 526518. SAARE M, H?MARIK U, VENTA R, et al. SP140L, an Evolutionarily recent member of the sp100 family, is an autoantigen in primary biliary cirrhosis[J]. J Immunol Res, 2015,2015(12): 526518.
3、 孙丽梅,王一鹏,刘燕敏,等. 抗线粒体抗体M2亚型在非原发性胆汁性肝硬化患者中的特点[J]. 中华肝脏病杂志, 2015, 23(5):343-349. 孙丽梅,王一鹏,刘燕敏,等. 抗线粒体抗体M2亚型在非原发性胆汁性肝硬化患者中的特点[J]. 中华肝脏病杂志, 2015, 23(5):343-349.
4、 ALI A H, CAREY E J, LINDOR K D. Diagnosis and management of primary biliary cirrhosis[J]. Expert Rev Clin Immunol, 2014, 10(12): 1667-1678. ALI A H, CAREY E J, LINDOR K D. Diagnosis and management of primary biliary cirrhosis[J]. Expert Rev Clin Immunol, 2014, 10(12): 1667-1678.
5、 HU S L, ZHAO F R, HU Q, et al. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis[J]. PloS one, 2014, 9(7): e101916. HU S L, ZHAO F R, HU Q, et al. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis[J]. PloS one, 2014, 9(7): e101916.
6、 GU E L, YAO G B. The clinical characteristics of primary biliary cirrhosis in China: a systematic review[J].Chin J Hepatol, 2009, 17(11): 861-866. GU E L, YAO G B. The clinical characteristics of primary biliary cirrhosis in China: a systematic review[J].Chin J Hepatol, 2009, 17(11): 861-866.
7、 HEGADE V S, BOLIER R, OUDE ELFERINK R P, et al. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis[J]. Frontline Gastroenterol 2016; 7(3): 158-166. HEGADE V S, BOLIER R, OUDE ELFERINK R P, et al. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis[J]. Frontline Gastroenterol 2016; 7(3): 158-166.
8、 AL-HARTHY N, KUMAGI T. Natural history and management of primary biliary cirrhosis [J]. Hepat Med, 2012, 11(4): 61-71. AL-HARTHY N, KUMAGI T. Natural history and management of primary biliary cirrhosis [J]. Hepat Med, 2012, 11(4): 61-71.
9、 陈成伟,成军,窦晓光,等. 原发性胆汁性肝硬化诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015(12): 1980-1988. 陈成伟,成军,窦晓光,等. 原发性胆汁性肝硬化诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015(12): 1980-1988.
10、 CAREY E J, ALI A H, LINDOR K D. Primary biliary cirrhosis [J]. Lancet,2015, 386(10003): 1565-1575. CAREY E J, ALI A H, LINDOR K D. Primary biliary cirrhosis [J]. Lancet,2015, 386(10003): 1565-1575.
11、 陈晶. AMA-M2和SP100联合检测对诊断PBC的意义[J]. 国际检验医学杂志, 2014, 35(18): 2554-2555. 陈晶. AMA-M2和SP100联合检测对诊断PBC的意义[J]. 国际检验医学杂志, 2014, 35(18): 2554-2555.
12、 詹克勤,彭卫华,陈建华,等. 抗gp210及sp100抗体在原发性胆汁性肝硬化患者中的临床研究[J]. 实验与检验医学, 2013, 31(5): 416-418. 詹克勤,彭卫华,陈建华,等. 抗gp210及sp100抗体在原发性胆汁性肝硬化患者中的临床研究[J]. 实验与检验医学, 2013, 31(5): 416-418.
13、 薛伟,朱烨. AMA-M2运用于原发性胆汁性肝硬化早期筛查的效果研究[J]. 河北医学, 2016, 22(1): 15-17. 薛伟,朱烨. AMA-M2运用于原发性胆汁性肝硬化早期筛查的效果研究[J]. 河北医学, 2016, 22(1): 15-17.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录